Aspire Biopharma, Inc. (NASDAQ: ASBP) is poised to disrupt the $100 billion global drug delivery market with its innovative, soluble sublingual technology. Recently listed on Nasdaq, Aspire’s system allows for rapid drug absorption, bypassing the gastrointestinal tract and liver, significantly enhancing efficacy while reducing side effects. With a broad application across FDA-approved drugs, nutraceuticals, and supplements, including a fast-acting sublingual aspirin, ED treatments, hormonal therapies, and various supplements, the potential is significant. Their lead product, sublingual aspirin, has been shown in initial studies to be able to deliver therapeutic levels in under two minutes, a potential game-changer for time-sensitive medical needs!
ASBP’s technology addresses critical healthcare challenges, including the opioid crisis, with its potential for non-opioid pain management. A seasoned management team is driving the company's clinical development and commercialization which focuses on improving existing drugs and utilizing their patent pending and proprietary delivery technology. To better understand Aspire Biopharma's vision and strategy, SmallCaps Daily sat down with ASBP’s CEO Kraig Higginson to discuss the company's disruptive technology and the expected clinical and corporate milestones for 2025.
Let’s dive right in.
Kraig Higginson – Chief Executive Officer
Mr. Higginson brings to Aspire BioPharma, Inc., extensive experience in early-stage growth company management as well as vast public market expertise. Mr. Higginson founded and served as Chief Executive Officer of VIA Motors, Inc., a hybrid electric vehicle company from November 2010 to January 2015, which achieved more than a $1 billion market cap. From October 2003 until November 2010, he founded and served as Chairman of the Board of Directors of Raser Technologies, a NYSE company which achieved a $1.7 billion market cap. Earlier, Mr. Higginson also founded American Telemedia Network, Inc., a publicly traded NASDAQ company that developed a nationwide satellite network broadcasting data for large corporations, as well as video programming and advertising to shopping centers and malls. He served as President and Chief Executive Officer of American Telemedia Network from 1984 through 1988. Mr. Higginson has been a leading entrepreneur for several decades. In 2010, Mr. Higginson was called to testify, as an expert, before Congress regarding the viability of vehicle electrification and was directly instrumental in pushing through the $7,500 per vehicle legislation, which is credited for launching the EV industry in the United States.
Full Interview:
Thank you for taking the time to speak with us about Aspire Biopharma. To start, could you please provide our readers with an overview of the company and its core mission?
Aspire Biopharma is dedicated to revolutionizing drug delivery through our disruptive, innovative, and soluble formulation technology. Unlike traditional biotech approaches, we focus on enhancing existing drugs rather than developing new ones. Our mission is to significantly improve the efficacy and patient experience of widely used pharmaceuticals. We like to say, "We don't make the drugs, we make them better."
You mentioned your flagship product, a sublingual aspirin. Could you elaborate on the advantages of this formulation compared to traditional aspirin products?
Absolutely. Our sublingual aspirin has shown in our initial testing to be able to achieve therapeutic bioavailability in less than two minutes compared to as much as 20-plus minutes required for traditional aspirin. This rapid onset is critical, especially in time-sensitive situations like heart attacks or strokes. Additionally, our formulation bypasses the gastrointestinal tract, minimizing any adverse effects commonly associated with oral aspirin, such as stomach irritation.
Beyond aspirin, what other applications does Aspire Biopharma's technology have?
Our technology is highly versatile and applicable to a wide range of drugs. We are currently exploring applications in various therapeutic areas, including pain management, erectile dysfunction, weight loss, and vitamin supplementation. We are also exploring how our technology can enhance medications like Semaglutide (Ozempic) and testosterone.
You mentioned the potential for licensing agreements with major pharmaceutical companies. What is your commercialization strategy, and how do you envision these partnerships?
Our primary strategy is to collaborate with established pharmaceutical companies through licensing agreements. This allows us to leverage their existing market presence and distribution networks. We aim to partner with companies like Bayer, Tylenol, and Pfizer, enabling them to introduce enhanced versions of their products using our technology. This model allows us to focus on our core strength: enhancing drug delivery.
Given the unique delivery method, how does Aspire Biopharma address dosing and potential toxicity concerns?
Our sublingual delivery method allows for significantly lower doses compared to traditional oral medications. In most cases, we require less than half the standard dose to achieve the same therapeutic effect. This reduces the risk of toxicity and adverse effects. Furthermore, because we bypass the GI tract, our formulations minimize the strain on the liver and kidneys. All components of our formulation are benign and pH-neutral, preventing any disruption to the oral environment.
Aspire Biopharma is also exploring vitamin and supplement applications. Could you elaborate on this aspect of your business?
Yes, we recognize the significant inefficiencies in traditional vitamin and supplement delivery. Our technology enables significantly higher absorption rates, maximizing the benefits of these products. We are initially focusing on popular vitamins like B12, melatonin, and multivitamins, aiming to enhance their efficacy and bioavailability.
You've mentioned a wide range of applications for your technology. Are there any specific products in your pipeline that you'd like to highlight?
We're particularly excited about a pre-workout product we're developing. The pre-workout supplement market is very popular, but current products typically take up to 30 minutes to take effect. Our formulation is expected to offer a significant advantage, delivering rapid absorption and beneficial effects within minutes. Imagine taking a small, convenient packet, like a Pixi Stick, placing it under your tongue, and feeling the benefits by the time you reach your first workout station. This has the potential to revolutionize how you prepare for your workouts.
Beyond licensing agreements, are you considering acquisitions as a growth strategy?
We are actively exploring acquisition opportunities to expand our reach and capabilities. We see significant potential in areas where our sublingual delivery can replace injections, such as insulin and weight loss medications like Semaglutide. Eliminating the need for needles improves patient compliance and comfort, which is a key focus for us.
How is Aspire Biopharma navigating the regulatory landscape, particularly with the FDA?
We are aiming for a streamlined approval process, especially for drugs like aspirin, where the active ingredient is already well-established. The FDA has shown a positive reception to our technology, recognizing its potential to enhance patient safety and efficacy.
Financially, where does Aspire Biopharma stand, and what are your near-term goals?
We have secured sufficient funding to support our operations through our initial product launches. We expect to launch our first nutritional product in Q2, followed by our first drug product, the sublingual aspirin, in Q3 or Q4. We are also actively exploring acquisition opportunities to further expand our technology and market reach.
What are the key priorities and milestones for Aspire Biopharma in achieving long-term growth?
Our key priorities include securing strategic partnerships, expanding our product portfolio, and demonstrating the broad applicability of our technology. We aim to establish Aspire Biopharma as a leading provider of enhanced drug delivery solutions.
Are there any challenges the company is currently facing now or in the coming years?
Like any biotech company, we face challenges related to regulatory approvals, market adoption, and competitive pressures. However, we have a focused strategy, a robust pipeline, and strong manufacturing and clinical partnerships that will help mitigate these challenges.
Is there anything else you would like to add for investors?
We believe that Aspire Biopharma is uniquely positioned to disrupt the pharmaceutical industry. Our technology offers significant advantages over traditional drug delivery methods, and we are confident in our ability to create substantial value for our shareholders.
Thank you for your time.
